Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomesStephen Johnston,Masakazu Toi,Joyce O'Shaughnessy,Priya Rastogi,Mario Campone,Patrick Neven,Chiun Sheng Huang,Jens Huober,Georgina Garnica Jaliffe,Irfan Cicin,Sara Tolaney,Matthew P. Goetz,Hope Rugo,Elzbieta Senkus,Laura Testa,Lucia Del Mastro,Chikako Shimizu,Ran Wei,Ashwin Shahir,Maria Munoz,Belen San Antonio,Valerie Andre, Nadia Harbeck,Miguel MartinCANCER RESEARCH（2023）引用 0|浏览7暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
